A Targeted Therapy for a Rare Disease
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S....
Progress Against Cancer
The FDA approved a kinase inhibitor for the treatment of inflammatory myofibroblastic tumors in children and adults. The U.S....
The CAR T-cell therapy lisocabtagene maraleucel was approved for the second-line treatment of certain patients with large B-cell lymphoma. ...
Ibrutinib, a small molecule inhibitor of B-cell proliferation, was approved for pediatric patients with chronic graft-versus-host disease. The U.S....
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E...
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma. The U.S....
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible...
The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA)...
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S....